| Similar Articles |
|---|
 |
The Motley Fool
July 5, 2011
Luke Timmerman |
Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Expectations are sky-high.   |
The Motley Fool
January 6, 2011
Brian Orelli |
$145 Million Down; Billions to Go Seattle Genetics signs up another partner. |
The Motley Fool
March 31, 2011
Brian Orelli |
Better Buy? Seattle Genetics or ImmunoGen Battle of the heat-seeking cellular missiles. |
The Motley Fool
February 9, 2007
Brian Lawler |
Picking Up the Pace at Seattle Genetics The cash situation shows the shares of this drug development company could be appealing. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
September 14, 2010
Brian Orelli |
This Bad News Could've Been Worse A Seattle Genetics drug fails, but there's more in the pipeline. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument. |
The Motley Fool
October 12, 2010
Brian Orelli |
This Drugmaker Stands on a Platform Above the Rest ImmunoGen signs up another partner. |
The Motley Fool
August 20, 2011
Luke Timmerman |
Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas. |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
The Motley Fool
September 27, 2010
Brian Orelli |
Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
BusinessWeek
May 9, 2005
Catherine Arnst |
Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
July 12, 2011
Luke Timmerman |
Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug. |
The Motley Fool
December 20, 2011
Luke Timmerman |
Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs What does this important collaboration mean for biosimilars? |
The Motley Fool
March 27, 2009
Brian Orelli |
Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
July 10, 2008
Brian Lawler |
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. |
The Motley Fool
July 13, 2011
Brian Orelli |
2 Questions for Seattle Genetics So far the FDA is fairly impressed with Seattle Genetics' lymphompa drug brentuximab vedotin. |
The Motley Fool
August 9, 2010
Luke Timmerman |
Kaleetan Seeks to Stand on Dendreon's Shoulders Kaleetan Pharmaceuticals tries to improve upon Dendreon's breakthrough cancer drug. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
The Motley Fool
November 2, 2004
Charly Travers |
Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. |
The Motley Fool
August 22, 2011
Brian Orelli |
Speedy in Seattle Seattle Genetics gets an early approval of Adcentris. |
The Motley Fool
April 2, 2008
Brian Lawler |
Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
March 26, 2007
Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. |
The Motley Fool
November 18, 2004
Charly Travers |
A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
BusinessWeek
September 19, 2005 |
Biotech, Then and Now Amgen's George Rathmann explains how Big Pharma's role has evolved from detractor to investor, and why R&D needs more respect. |
The Motley Fool
April 8, 2011
Brian Orelli |
ImmunoGen's Hot Start ImmunoGen scores some positive data, but were investors expecting less? |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
The Motley Fool
August 31, 2011
Brian Orelli |
Antibodies: They're Not Just for Fighting Infection Anymore Therapeutic antibodies have continued to evolve since the first, OKT3, was approved back in 1986. Biotech investors had better pay attention, lest the technology passes them by. |
The Motley Fool
October 12, 2010
Brian Orelli |
Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Bio-IT World
June 15, 2003
Barbara Depompa |
Southwest Region Texas: Bioscience with a Space Spin... New Mexico: Building a Bioinformatics Niche... Arizona: Focus on Cancer and Neurological Therapy... Southern California: Deep Biotech Roots Grow Many Branches... Northern California: 'Can You Afford To Be Elsewhere?'... |
Scientific American
March 2009
Elaine Schattner |
A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment |
The Motley Fool
July 14, 2011
Luke Timmerman |
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel An FDA panel of cancer drug experts recommended in a 10-0 vote that the company's drug for Hodgkin's lymphoma should be cleared for sale in the U.S. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
The Motley Fool
December 8, 2010
Brian Orelli |
Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Bristol-Myers Almost Ready to Seal the Deal With ZymoGenetics ZymoGenetics, one of the driving forces of Seattle biotech the past 30 years, is about to become a thing of the past. |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
The Motley Fool
June 21, 2010
Erin Kutz |
Curis Misses Mark in Drug Trial; Genzyme Elects Board; GTC Cuts Jobs; and More Boston-Area Life Sciences News These drug and biomedical companies made news last week. |
